Pharmacological characterization of antagonists of the C5a receptor

British Journal of Pharmacology

Volumn 128, Issue 7, 1999, Pages 1461-1466

  Paczkowski, Natalii J ^a   Finch, Angela M ^a   Whitmore, Jacqueline B ^a   Short, Anna J ^a   Wong, Allan K ^a   Monk, Peter N ^a   Cain, Stuart A ^a   Fairlie, David P ^a   Taylor, Stephen M ^a  

^a NONE

Author keywords

C5a; C5a antagonist; C5a receptor; Insurmountable antagonism

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR ANTAGONIST; MEMBRANE RECEPTOR; MYELOPEROXIDASE; PEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTERY CONSTRICTION; ARTICLE; BINDING AFFINITY; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; HUMAN TISSUE; NEUTROPHIL; PRIORITY JOURNAL; UMBILICAL ARTERY;

EID: 0032707745     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702938     Document Type: Article

References (40)

1. ARAI, H. & CHARO, I.F. (1996). Differential regulation of G-protein-mediated signaling by chemokine receptors. J. Biol. Chem., 271, 21814-21819.
2. BAUTSCH, W., EMDE, M., KRETZSCHMAR, T., KOHL, J., SUCKAU, D. & BITTER, S.D. (1992). Human C5a anaphylatoxin: gene cloning and expression in Escherichia coli. Immunobiol., 185, 41-52.
3. BOULAY, F., MERY, L., TARDIF, M., BROUCHON, L. & VIGNAIS, P. (1991). Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochem., 30, 2993-2999.
4. RUBECK, P., GROTZINGER, J., WINKLER, M., KOHL, J., WOLLMER, A., KLOS, A. & BAUTSCH, W. (1994). Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor. Eur. J. Biochem., 219, 897-904.
5. CHENOWETH, D.E. & HUGLI, T.E. (1980). Human C5a and C5a analogs as probes of the neutrophil C5a receptor. Mol. Immunol., 17, 151-161.
6. CLANCY, R.M., DAHINDEN, C.A. & HUGLI, T.E. (1985). Complement-mediated arachidonate metabolism. Prog. Biochem. Pharmacol., 20, 120-131.
7. DEMARTINO, J.A., VAN RIPER, G., SICILIANO, S.J., MOLINEAUX, C.J.. KONTEATIS, Z.D., ROSEN, H. & SPRINGER, M.S. (1994). The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J. Biol. Chem., 269, 14446-14450.
8. DRAPEAU, G., BROCHU, S., GODIN, D., LEVESQUE, L., RIOUX, F. & MARCEAU, F. (1993). Synthetic C5a receptor agonists. Pharmacology, metabolism and in vivo cardiovascular and hematologic effects. Biochem. Pharmacol., 45, 1289-1299.
9. EMBER, J.A., SANDERSON, S.D., HUGLI, T.E. & MORGAN, E.L. (1994). Induction of interleukin-8 synthesis from monocytes by human C5a anaphylatoxin. Am. J. Pathol., 144, 393-403.
10. EMBER, J.A., SANDERSON, S.D., TAYLOR, S.M., KAWAHARA, M. & HUGLl, T.E. (1992). Biologic activity of synthetic analogues of C5a anaphylatoxin. J. Immunol., 148, 3165-3173.
11. FEDERWISCH, M., WOLLMER, A., EMDE, M., STUHMER, T., MELCHER, T., KLOS, A., KOHL, J. & BAUTSCH, W. (1993). Tryptophan mutants of human C5a anaphylatoxin: a fluorescence anisotropy decay and energy transfer study. Biophys. Chem., 46, 237-248.
12. FINCH, A., VOGEN, S., SHERMAN, S., KIRNARSKY, L., TAYLOR, S. & SANDERSON, S. (1997). Biological active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J. Med. Chem., 40, 877-884.
13. FINCH, A.M., WONG, A.K., PACZKOWSKI, N.J., WADI, S.K., CRAIK, D.J., FAIRLIE, D.P., TAYLOR, S.M. (1999). Low molecular weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem., 42, 1965-1974.
14. FLOREANI, A.A., HEIRES, A.J., WELNIAK, L.A., MILLER-LINDHOLM, A., CLARK-PIERCE, L., RENNARD, S.I., MORGAN, E.I., & SANDERSON, S.D. (1998), Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J. Immunol., 160, 5073-5081.
15. GASQUE, P., SINGHRAO, S.K., NEAL, J.W., GOTZE, O. & MORGAN. B.P. (1997). Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am. J. Pathol., 150, 31-41.
16. GERARD, C. & GERARD, N.P. (1994). C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu. Rev. Immunol., 12, 775-808.
17. GERARD, N.P. & GERARD, C. (1991). The chemotactic receptor for human C5a anaphylatoxin. Nature, 349, 614-617.
18. GERARD, N.P., BAO, L., XIAO, P.H., EDDY, R.J., SHOWS, T.B. & GERARD, C. (1993). Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene. Biochem., 32, 1243-1250.
19. HAVILAND, D.L., MCCOY, R.L., WHITEHEAD, W.T., AKAMA, H., MOLMENTI, E.P., BROWN, A., HAVILAND, J.C., PARKS, W.C., PERLMUTTER, D.H. & WETSEL, R.A. (1995). Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol., 154, 1861-1869.
20. KAWAI, M., QUINCY, D.A., LANE, B., MOLLISON, K.W., LULY, J.R. & CARTER. G.W. (1991). Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem., 34, 2068-2071.
21. KENAKIN, T.P. (1997). Pharmacologic analysis of drug-receptor interaction. New York: Lippincott-Raven.
22. KONTEATIS, Z.D., SICILIANO, S.J., VAN, R.G., MOLINEAUX, C.J., PANDYA, S., FISCHER, P., ROSEN, H., MUMFORD, R.A. & SPRINGER, M.S. (1994). Development of C5a receptor antagonists. Differential loss of functional responses. J. Immunol., 153, 4200-4205.
23. MARCEAU, F., LUNDBERG, C. & HUGLI, T.E. (1987). Effects of the anaphylatoxins on circulation. Immunopharmacol., 14, 67-84.
24. MCCOY, R., HAVILAND, D.L., MOLMENTI, F.P., ZIAMBARAS, T., WITSEL, R.A. & PERLMUTTFR, D.H. (1995). N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation. J. Exp. Med., 182, 207-217.
25. MOLLISON, K.W., MANDECKI, W., ZUIDERWEG, E.R., FAYER, L., FEY, T.A., KRAUSE, R.A., CONWAY, R.G., MILLER, L., EDALJI, R.P., SHALLCROSS, M.A. & et al. (1989). Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis. Proc. Natl. Acad. Sci. U.S.A., 86, 292-296.
26. MONK, P.N., PEASE, J.E. & BARKER, M.D. (1994). C5a Stimulus-Secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins. Biochem. Mol. Biol. Int., 32, 13-20.
27. MORGAN, E.L., SANDERSON, S., SCHOLZ, W., NOONAN, D.J., WEIGLE W.O. & HUGLI T.E. (1992). Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis. J. Immunol., 148, 3937-3942.
28. ROLLINS, T.E., SICILIANO, S. & SPRINGER, M.S. (1988). Solubilization of the functional C5a receptor from human polymorphonuclear leukocytes. J. Biol. Chem., 263, 520-526.
29. SANDERSON, S.D., KIRNARSKY, L., SHERMAN, S.A., EMBER, J.A., FINCH, A.M. & TAYLOR, S.M. (1994). Decapeptide agonists of human C5a: the relationship between conformation and spasmogenic and platelet aggregatory activities. J. Med. Chem., 37, 3171-3180.
30. SANDERSON, S.D., KIRNARSKY, L., SHERMAN, S.A., VOGEN, S.M., PRAKASH, O., EMBER, J.A., FINCH, A.M. & TAYLOR, S.M. (1995). Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response. J. Med. Chem., 38, 3669-3675.
31. SHORT, A., WONG, A.K., FINCH, A.M., HAAIMA, G., SHIELS, I.A., FAIRLIE, D.P., TAYLOR, S.M. (1999). Effects of a new C5a receptor antagonist on C5a-and endotoxin-induced neutropenia in the rat. Br. J. Pharmacol., 126, 551.
32. SHUM, J.K., ALLEN, R.A. & WONG, Y.H. (1995). The human chemoattractant complement C5a receptor inhibits cyclic AMP accumulation through Gi and Gz proteins. Biochem. Biophys. Res. Commun., 208, 223-239.
33. SICILIANO, S.J., ROLLINS, T.E., DEMARTINO, J., KONTEATIS, Z., MALKOWITZ, L., VAN, R.G., BONDY, S., ROSEN, H. & SPRINGER, M.S. (1994). Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A., 91, 1214-1218.
34. SICILIANO, S.J., ROLLINS, T.E. & SPRINGER, M.S. (1990). Interaction between the C5a receptor and Gi in both the membrane-bound and detergent-solubilized states. J. Biol. Chem., 265, 19568-19574.
35. TAYLOR. S.M., FINCH, A.M., HERON, A.E., BROWN, L.C. & FLORIN, T.H. (1994). Reversibility of tachyphylaxis to C5a in guinea pig tissues, perfused human placental lobule, and umbilical artery. Inflammation, 18, 645-657.
36. TEMPERO, R.M., HOLLINGSWORTH, M.A., BURDICK, M.D., FINCH, A.M., TAYLOR, S.M., VOGEN, S.M., MORGAN, E.L. & SANDERSON, S.D. (1997). Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J. Immunol., 158, 1377-1382.
37. VOGEN, S.M., FINCH, A.M., WADI, S.K. THATCHER, J., MONK, P.N., TAYLOR, S.M. & SANDERSON, S.D. (1999). The influence of Lys68 in decapeptide agonists of C5a on C5a receptor binding, activation and selectivity. J. Pep. Res., 53, 8-17.
38. WERFEL, L., ZWIRNER, J., OPPERMANN, M., SIEBER, A., BEGEMANN, G., DROMMER, W., KAPP, A. & GOTZE, O. (1996). CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin. J. Immunol., 157, 1729-1735.
39. WHALEY, K. (1987). Complement in health & disease. MTP Press Ltd. Lancaster.
40. WONG, A.K., FINCH, A.M., PIERENS, G.K., CRAIK, D.J., TAYLOR, S.M. & FAIRLIE, D.P. (1998). Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J. Med. Chem., 41, 3417-3425.